theMednetRegister

Pediatric Hematology/Oncology

ASH 2024   

Questions discussed in this category

With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
Based on AALL1731, if in maintenance, is there a certain point at which it is incorporated, or a certain maintenance cycle which it is no longer offer...
1 Answer available

Related Topics in Pediatric Hematology/Oncology

Copyright © 2025 theMednet
All Rights Reserved.